Atea Pharmaceuticals, Inc.AVIRNASDAQ
LOADING
|||

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
4 analysts·Low coverage
25%
Rating Distribution
Strong Buy
00%
Buy
125%
Hold
250%
Sell
125%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 70% higher.

Bear Case
$6.88
+70%
Consensus
$6.88
+70%
Bull Case
$6.88
+70%
Price Range4 analysts
Low
Consensus
High
$6.88
$6.88
Current Target
Current Price
$4.06
Upside to Target
$2.82

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.75(1 analysts)
Actual
Estimate
Range (Low–High)
Stock Alarm Pro
Forward Growth Estimates (YoY)
FY2027
Rev+436.25%
EPS

Earnings Surprises

Beat rate:67%(8/12 quarters)
Avg surprise:+8.5%
Beat
Miss
Inline
Estimate
Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Aug 12, 2024Morgan Stanley
Morgan Stanley Upgrades Atea Pharmaceuticals (AVIR) to Equalweight, 'HCV opportunity comes into focus, while COVID outcome remains uncertain'
Target:$6.88
+105.4%from $3.35